Establishment Labs Holdings Inc. (ESTA) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Establishment Labs published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Establishment Labs files with the SEC as a U.S. domestic filer (Form 10-Q and 10-K), although it is incorporated in the British Virgin Islands and manufactures in Costa Rica.
• Establishment Labs reports no adjusted EPS. Its non-GAAP measures are adjusted gross margin, adjusted operating expenses and Adjusted EBITDA.

Source: Establishment Labs Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

From the earnings release

In its Q3 2026 release, Establishment Labs said:

“Increasing revenue to more than $274 million, compared to the previous guidance of $269 million to $271 million.”

“Adjusted Gross Margin of approximately 70.7%, reflecting a higher-than-anticipated mix of OUS distributor sales.”

“Adjusted Operating Expenses of $195 million to $200 million, unchanged.”

“Positive Adjusted EBITDA for the full year.”

Source: Establishment Labs Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ESTA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and GAAP basic and diluted net loss per share, each as first reported in that quarter's release.

We do not hold a confirmed date for Establishment Labs's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Establishment Labs reported revenue of $72.0 million in Q3 2026, up 33.9% from $53.8 million a year earlier. U.S. revenue rose 119.0% to $26.0 million and revenue outside the U.S. (OUS) rose 9.7% to $46.0 million. In dollar terms the 10-Q puts the increase at $14.2 million from the United States and $4.1 million from everywhere else. (Establishment Labs Q3 2026 release, Oct 29, 2026; Establishment Labs Form 10-Q, Q3 2026, Nov 6, 2026)

Establishment Labs' core product is the Motiva line of silicone gel-filled breast implants. It began selling Motiva Implants for breast augmentation in the United States in October 2024, and outside the U.S. it sells through a mix of direct and distributor sales. Its minimally invasive platform, Mia Femtech and Preservé, grew 124.0% year over year to approximately $9 million of revenue in the quarter. (Establishment Labs Form 10-Q, Q3 2026, Nov 6, 2026; Establishment Labs Form 10-K, 2025, Feb 27, 2026; Establishment Labs Q3 2026 release, Oct 29, 2026)

Establishment Labs' U.S. commercial footprint passed 2,100 accounts in the quarter, with more than 400 plastic surgeons trained on Preservé. The FDA approved additional smaller Motiva implant sizes, and the company says FDA review of Motiva for breast reconstruction is progressing in line with its expectations. (Establishment Labs Q3 2026 release, Oct 29, 2026)

Establishment Labs' GAAP gross margin was 69.1%, against 70.1% a year earlier. Gross profit included $1.3 million of inventory charges associated with restructuring; excluding them, adjusted gross margin was 70.8%. The 10-Q also attributes the decline to a higher mix of lower-margin distributor sales outside the United States, partly offset by U.S. growth and the minimally invasive portfolio. (Establishment Labs Q3 2026 release, Oct 29, 2026; Establishment Labs Form 10-Q, Q3 2026, Nov 6, 2026)

Establishment Labs' GAAP net loss was $10.7 million, or $0.35 per share, in Q3 2026, against $11.1 million, or $0.38, a year earlier. It reports no adjusted EPS. Adjusted EBITDA rose to $6.4 million, or 8.9% of revenue, from $1.2 million, or 2.2%, and excludes share-based compensation ($2.9 million), litigation matters ($1.3 million), inventory charges associated with restructuring ($1.3 million) and restructuring charges and other ($1.5 million). (Establishment Labs Q3 2026 release, Oct 29, 2026)

Interest on its debt is the main gap between Establishment Labs' operating loss of $2.6 million and its net loss. Interest expense was $6.8 million in the quarter. In April 2026 it entered into an amended credit agreement for term loans of up to $300 million and drew a first tranche of $265 million on April 30, 2026, using about $259 million to repay its previous credit agreement and transaction costs. Note payable stood at $267.8 million at September 30, 2026. (Establishment Labs Q3 2026 release, Oct 29, 2026; Establishment Labs Form 10-Q, Q3 2026, Nov 6, 2026)

Weighted average shares used for basic and diluted net loss per share were 30,430,805, against 29,622,101 a year earlier. Net cash provided by operating activities was approximately $7.7 million and free cash flow $5.1 million, which Establishment Labs called the first positive quarter in its history. (Establishment Labs Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Establishment Labs gives a full-year outlook in its release. With Q3 2026 it raised its 2026 revenue guidance to more than $274 million, from $269 million to $271 million, set adjusted gross margin at approximately 70.7% because of a higher mix of OUS distributor sales, kept adjusted operating expenses at $195 million to $200 million, and expects positive Adjusted EBITDA for the year. (Establishment Labs Q3 2026 release, Oct 29, 2026)

In the release, CEO Peter Caldini said Establishment Labs expects fiscal 2027 to deliver growth of 25% and positive cash flow. Through nine months, revenue was $199.4 million against $146.5 million a year earlier. (Establishment Labs Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Establishment Labs, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Establishment Labs's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ESTA is on is ESTA a buy or a sell?, what analysts expect next is on the ESTA forecast, and what the company does is on the Establishment Labs Holdings Inc. (ESTA) stock page.

Every number on this page can be traced to a document Establishment Labs published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.